One of the highly expressed transcription factors in Msi2-expressing CSCs is the nuclear hormone receptor RORγ, which controls both stemness and proto-oncogenic transcriptional programs and could be pharmacologically targeted to reduce tumour burden in human and murine models. The gene discussed is MSI2; the disease is neoplasm.